173 related articles for article (PubMed ID: 12679640)
1. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.
Dickens DS; Kozielski R; Leavey PJ; Timmons C; Cripe TP
J Pediatr Hematol Oncol; 2003 Apr; 25(4):282-5. PubMed ID: 12679640
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 expression in pediatric sarcomas.
Dickens DS; Kozielski R; Khan J; Forus A; Cripe TP
Pediatr Dev Pathol; 2002; 5(4):356-64. PubMed ID: 12024286
[TBL] [Abstract][Full Text] [Related]
3. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.
Dickens DS; Cripe TP
J Pediatr Hematol Oncol; 2003 Sep; 25(9):709-14. PubMed ID: 12972806
[TBL] [Abstract][Full Text] [Related]
4. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
Rodriguez NI; Hoots WK; Koshkina NV; Morales-Arias JA; Arndt CA; Inwards CY; Hawkins DS; Munsell MF; Kleinerman ES
J Pediatr Hematol Oncol; 2008 Jul; 30(7):507-12. PubMed ID: 18797196
[TBL] [Abstract][Full Text] [Related]
5. Disparity in Outcomes for Adolescent and Young Adult Patients Diagnosed With Pediatric Solid Tumors Across 4 Decades.
Chen I; Pasalic D; Fischer-Valuck B; Frangoul H; DeWees T; Shinohara ET; Perkins SM
Am J Clin Oncol; 2018 May; 41(5):471-475. PubMed ID: 27841802
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma.
Carmody Soni EE; Miller BJ; Scarborough MT; Reith J; Gibbs CP
Oncol Rep; 2011 Dec; 26(6):1513-7. PubMed ID: 21874258
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
9. Pediatric sarcoma in Central America: outcomes, challenges, and plans for improvement.
Friedrich P; Ortiz R; Strait K; Fuentes S; Gamboa Y; Arambú I; Ah-Chu-Sanchez M; London W; Rodríguez-Galindo C; Antillón-Klussmann F; Báez F;
Cancer; 2013 Feb; 119(4):871-9. PubMed ID: 22972687
[TBL] [Abstract][Full Text] [Related]
10. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
[TBL] [Abstract][Full Text] [Related]
11. [Detection and activity analysis of gelatinases in bone and soft tissue tumors].
Hua C; Wen Y; Wang C; Li L
Hua Xi Yi Ke Da Xue Xue Bao; 2000 Mar; 31(1):82-5. PubMed ID: 12501622
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Neutrophil-to-Lymphocyte Ratio and Lymphocyte Recovery: Independent Prognostic Factors for Survival in Pediatric Sarcomas.
Vasquez L; León E; Beltran B; Maza I; Oscanoa M; Geronimo J
J Pediatr Hematol Oncol; 2017 Oct; 39(7):538-546. PubMed ID: 28697168
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary treatment for childhood sarcoma.
Jaffe N; Murray J; Traggis D; Cassady RJ; Filler RM; Watts H; Weichselbaum R; Weinstein H
Am J Surg; 1977 Apr; 133(4):405-13. PubMed ID: 300570
[TBL] [Abstract][Full Text] [Related]
14. Analysis of prognostic factors of pediatric-type sarcomas in adult patients.
Ahn HK; Uhm JE; Lee J; Lim DH; Seo SW; Sung KS; Lee SJ; Lee DJ; Baek KK; Kim WS; Park JO
Oncology; 2011; 80(1-2):21-8. PubMed ID: 21606660
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor.
Moalic S; Liagre B; Le Bail JC; Beneytout JL
Int J Oncol; 2001 Mar; 18(3):533-40. PubMed ID: 11179483
[TBL] [Abstract][Full Text] [Related]
16. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
17. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.
Shirahama T; Arima J; Akiba S; Sakakura C
Cancer; 2001 Jul; 92(1):188-93. PubMed ID: 11443626
[TBL] [Abstract][Full Text] [Related]
18. Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.
Fukushima T; Ogura K; Akiyama T; Takeshita K; Kawai A
BMC Musculoskelet Disord; 2018 Aug; 19(1):297. PubMed ID: 30121085
[TBL] [Abstract][Full Text] [Related]
19. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer.
Kim SI; Kwon SM; Kim YS; Hong SJ
Urology; 2002 Nov; 60(5):816-21. PubMed ID: 12429306
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy.
O'Connor JK; Avent J; Lee RJ; Fischbach J; Gaffney DK
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1034-40. PubMed ID: 15001242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
